Research and Markets has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2016" report to their offering.
Cedar Pollen Allergy pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Cedar Pollen Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Treatment includes antihistamines and decongestants. The molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.
Key Topics Covered:
- Introduction
- Cedar Pollen Allergy Overview
- Therapeutics Development
- Pipeline Products for Cedar Pollen Allergy - Overview
- Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
- Cedar Pollen Allergy - Therapeutics under Development by Companies
- Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
- Cedar Pollen Allergy Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Cedar Pollen Allergy - Products under Development by Companies
- Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
- Cedar Pollen Allergy - Companies Involved in Therapeutics Development
- ALK-Abello A/S
- Astellas Pharma Inc.
- Circassia Pharmaceuticals Plc
- Immunomic Therapeutics, Inc.
- Japan Tobacco Inc.
- REGiMMUNE Corporation
For more information about this report visit http://www.researchandmarkets.com/research/2ph7k6/cedar_pollen
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006433/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Allergy
Drugs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.